Dendritic cell–derived exosomes as immunotherapies in the fight against cancer

JM Pitt, M Charrier, S Viaud, F André… - The Journal of …, 2014 - journals.aai.org
The Journal of Immunology, 2014journals.aai.org
Exosomes are nanometric membrane vesicles of late endosomal origin released by most, if
not all, cell types as a means of sophisticated intercellular communication. A multitude of
studies showed how exosomes can mediate and regulate immune responses against
tumors. Dendritic cell–derived exosomes (Dex) have received much attention as
immunotherapeutic anticancer agents since the discovery that they harbor functional MHC–
peptide complexes, in addition to various other immune-stimulating components, that …
Abstract
Exosomes are nanometric membrane vesicles of late endosomal origin released by most, if not all, cell types as a means of sophisticated intercellular communication. A multitude of studies showed how exosomes can mediate and regulate immune responses against tumors. Dendritic cell–derived exosomes (Dex) have received much attention as immunotherapeutic anticancer agents since the discovery that they harbor functional MHC–peptide complexes, in addition to various other immune-stimulating components, that together facilitate immune cell–dependent tumor rejection. The therapeutic potential of Dex has been substantiated with their development and clinical testing in the treatment of cancer. This review focuses on mechanisms by which Dex interact with and influence immune cells and describes how they can be engineered to promote their immunogenic capacity as novel and dynamic anticancer agents.
journals.aai.org